July 23: India’s pharmaceutical and healthcare sectors continued to attract strong investor interest, with deal activity remaining resilient at $13.9 billion in the second quarter of 2026, reflecting confidence in the long-term growth potential of the industry.
The sector maintained momentum amid evolving global market conditions, supported by rising healthcare demand, innovation-driven growth, and increasing investments in pharmaceuticals, biotechnology, and healthcare services.
Industry analysts said the continued strength in deal values highlights the attractiveness of India’s healthcare ecosystem, backed by expanding domestic consumption, advanced manufacturing capabilities, and growing opportunities in research and development.
The pharma and healthcare sectors have witnessed increased strategic investments as companies focus on strengthening capabilities, expanding market reach, and developing new technologies and treatments.
Experts noted that India’s growing healthcare needs, favourable business environment, and role as a major global pharmaceutical supplier continue to support investor confidence.
The resilient deal activity underscores the sector’s importance in India’s economic growth story and its expanding role in the global healthcare landscape.
